# Tesamorelin References: Cited Studies and the FDA Label

> Tesamorelin references — the peer-reviewed trials, pharmacokinetic analyses, the NIH LiverTox monograph, and the FDA prescribing information cited across this research digest.

Each quantitative claim on this site maps to a numbered entry below — peer-reviewed trials, pharmacokinetic analyses, the NIH LiverTox monograph, and the FDA prescribing information.

## Cited sources

Every figure cited across this tesamorelin digest resolves to one of the numbered references below. Primary trials are listed with PubMed identifiers and DOIs; the regulatory and drug-safety sources link to the FDA prescribing information and the NIH LiverTox monograph. This site is an editorial summary of these published sources; the numbered [study references](/references) below are the basis for every figure, with deeper context on the [visceral-fat research](/research) and [tesamorelin half-life](/half-life) pages.

## References

[1] Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
[2] Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. https://pubmed.ncbi.nlm.nih.gov/18690162/
[3] Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/
[4] Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. https://pubmed.ncbi.nlm.nih.gov/20943777/
[5] National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH); 2018. https://www.ncbi.nlm.nih.gov/books/NBK548730/
[6] Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015;54(3):285-294. https://pubmed.ncbi.nlm.nih.gov/25358450/
[7] Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015;42(3):287-299. https://pubmed.ncbi.nlm.nih.gov/25895899/
[8] Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100:49-58. https://pubmed.ncbi.nlm.nih.gov/17214611/
[9] Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm. 2004;276:75-81. https://pubmed.ncbi.nlm.nih.gov/15113616/
[10] Teng S, et al. Impact of tesamorelin, a growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers. Clin Pharmacol Drug Dev. 2013;2:237-245. https://pubmed.ncbi.nlm.nih.gov/27121785/
[11] Kanashiro-Takeuchi RM, Takeuchi LM, et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci U S A. 2012;109:559-563. https://pubmed.ncbi.nlm.nih.gov/22203988/
[12] Yen DW, Sherman KE. Causes and outcomes of hepatic fibrosis in persons living with HIV. Curr Opin HIV AIDS. 2022;17:359-367. https://pubmed.ncbi.nlm.nih.gov/36165079/
[13] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. https://pubmed.ncbi.nlm.nih.gov/41545261/
[14] Arora G, Conde KR, Desouza CV. Pharmacologic treatments for the preservation of lean body mass during weight loss. J Clin Med. 2026;15(2):541. https://pubmed.ncbi.nlm.nih.gov/41598480/
[15] Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41476424/

---

tesamorelin catalogued cell by cell on a nine-panel reference board — every visceral-fat figure, the minutes-fast plasma clearance against the day-long IGF-1 effect, and the FDA-approved-only-for-HIV-lipodystrophy boundary filed to its study; a laboratory reference grid, not a clinic, a vendor, or a prescription.